在轴性脊椎关节炎中选择治疗和向治疗
Kalliopi Klavdianou1,2, Xenofon Baraliakos1
1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstr. 45, Herne, 44649, Germany.
Rheumatology (Oxford, England)
|September 26, 2025
概括
轴性脊椎关节炎 (axSpA) 的药理管理已经通过新的生物药物和JAK抑制剂得到改善. 个性化治疗选择考虑疾病表型,并发症和生育能力,以获得最佳的患者结果.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 轴性脊柱关节炎 (axSpA) 的药理管理已经显著进步.
- 有针对TNF-alpha和IL-17以及JAK抑制剂的生物制剂的新证据.
- 对axSpA患者的治疗选择仍然具有挑战性,因为症状异质性和反应多样化.
研究的目的:
- 讨论已批准的治疗方式对不同的axSpA表现的选择性影响.
- 评估治疗对肌肉骨外表现和并发症的影响.
- 在选择axSpA疗法时考虑生育和怀孕结果.
主要方法:
- 对生物药物 (TNF-α,IL-17抑制剂) 和JAK抑制剂的长期疗效和安全性的累积证据的审查.
- 在治疗决策中分析疾病表型,肌肉骨外表现和并发症.
- 考虑患者特定的因素,包括生育能力和怀孕结果.
主要成果:
- 现在有多种药理选择可用于axSpA管理.
- 由于患者异质性,个性化医疗方法至关重要.
- 伴随性疾病和生育/怀孕因素影响药物选择.
结论:
- 了解axSpA表型和肌肉骨外表现是个性化治疗的关键.
- 伴随性疾病需要根据疗效和安全性概况进行仔细的药物选择.
- 治疗策略必须考虑生育年龄患者的生育能力和怀孕.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493


